GLP-3+ - 4.9MG / 0.1MGのレビュー

GLP-3+ | Product Description GLP-3+ | Introduction GLP-3+ is a research-use-only co-formulated blend pairing a triple agonist incretin/glucagon analog (GLP-3, retatrutide-class — GLP-1 + GIP + Glucagon) with a fractional inclusion of a dual GLP-1/GIP agonist (tirzepatide-class). The composition supports in vitro investigations into layered incretin signaling, comparative receptor engagement, and multi-pathway metabolic modeling. Not intended for diagnostic or therapeutic use. Layered triple + dual incretin/glucagon signaling models Comparative pathway engagement vs. single-component analogs Energy balance, mitochondrial efficiency, and redox response assessments At a Glance: Co-Formulated Blend · GLP-3 Triple Agonist + Fractional Dual GLP-1/GIP Agonist · ≥99% Each (HPLC) · 5–50MG Vials GLP-3+ | Blend Composition by SKU SKU GLP-3 (Triple Agonist) Dual GLP-1/GIP Agonist Ratio GLP-3+ 5 mg 5 mg 0.1 mg 50:1 GLP-3+ 10 mg 10 mg 0.5 mg 20:1 GLP-3+ 20 mg 20 mg 0.5 mg 40:1 GLP-3+ 30 mg 30 mg 1 mg 30:1 GLP-3+ 40 mg 40 mg 1 mg 40:1 GLP-3+ 50 mg 50 mg 1.5 mg 40:1 Total mass per vial = GLP-3 fraction + dual-agonist fraction. Co-lyophilized for uniform reconstitution. GLP-3+ | Molecular Identity & Composition Component 1 — GLP-3 (Triple Agonist) Name GLP-3 Research Analog (Triple GLP-1 + GIP + Glucagon Agonist) Sequence 39-aa peptide with lipidation; KEGG motif: YXQGTFTSDY SILLDKKAQX AFIEYLLEGG PSSGAPPPS (X = non-canonical residue) Molecular Formula C221H342N46O68 Molecular Weight ≈4731.34 g/mol (free base) CAS Number 2381089-83-2 Component 2 — Dual GLP-1/GIP Agonist Name Dual GLP-1/GIP Receptor Agonist Research Analog Sequence 39-aa peptide with C20 fatty diacid lipidation at Lys20 (γGlu-2xAEEA linker) Molecular Formula C225H348N48O68 Molecular Weight ≈4813.45 g/mol (free base) CAS Number 2023788-19-2 Shared Specifications Appearance White to off-white lyophilized powder (co-lyophilized blend) Solubility Soluble in sterile water or bacteriostatic water Purity (each component) ≥99% (HPLC) Storage Guidelines • Lyophilized: ≤0°F (–18°C), dry, protected from light • Reconstituted: 36–46°F (2–8°C); avoid repeat freeze–thaw • Long-Term: Keep dry and frozen until use LuvionBio Quality Advantage Purity & Identity: ≥99% per component | HPLC & MS validated Endotoxin & Sterility: <0.05 EU/mg | Third-party verified Stability & Process: Controlled nucleation lyophilization | Co-lyophilized for uniform reconstitution Formulation & QA: PhD-Formulated | GMP / ISO-Aligned manufacturing Packaging: Luxe Fridge-Ready Box Category Overview | Multi-Receptor Bioenergetic Pathway Modulators Multi-component incretin blends are used in RUO studies to model how layered receptor engagement shapes downstream metabolic, mitochondrial, and redox-sensitive signaling. Combining a triple-agonist analog with a fractional dual-agonist enables comparative pathway modeling that single-component analogs cannot replicate, supporting research into receptor cross-talk, signal integration, and adaptive energy regulation. Exciting Areas of Study Comparative single-, dual-, and triple-receptor signaling in cell-based assays Pathway integration and receptor cross-talk in metabolic models ATP output and mitochondrial efficiency under layered agonist exposure Stress-induced metabolic pathway behavior in controlled assays Insulin-signaling and glucose-handling pathways in cell-based assays GLP-3+ | Research Modeling & Applications Characterize layered triple + dual receptor signaling vs. metabolic outputs Benchmark blend responses against single-component GLP-3 and dual-agonist controls Evaluate stress-adaptive energy regulation under multi-pathway exposure Model receptor desensitization and signal integration kinetics in vitro Research Use Disclaimer This product is supplied for laboratory research use only (RUO) and is intended solely for qualified professionals in a controlled research setting. It is not a drug, food, dietary supplement, cosmetic, or medical device, and is not intended for human or veterinary use or for any diagnostic, therapeutic, or clinical application. It is not for household use. No statement on this page has been evaluated by the U.S. Food and Drug Administration. Nothing herein is intended to diagnose, treat, cure, or prevent any disease, nor to suggest any dosage, route, or method of administration. LuvionBio makes no representation or warranty, express or implied, regarding fitness for any purpose other than research and provides no medical or professional advice. The purchaser and end user assume full responsibility for safe handling, storage, and use in accordance with all applicable laws, regulations, and institutional safety protocols, and accept all associated risk and liability. See our Terms & Conditions and our Research Compliance Disclaimers for complete terms.